Industry news that matters to you.  Learn more

Archives for June 2011

National Parkinson Foundation Awards More Than $1 Million for Research

The National Parkinson Foundation (NPF) has awarded more than $1 million dollars in clinical research projects in 2011. Through NPF’s individual investigators awards program, NPF is supporting work to advance three key areas of Parkinson’s disease (PD): 1) an advanced biomarker study, 2) a clinical trial to treat memory impairment, and 3) a study of the effectiveness of a treatment for sleep apnea in PD.

Exonhit Reports Key Progress in the Introduction of AclarusDx in the French IVD Market

Exonhit announced today the signature of an agreement with Almac Diagnostics Limited which will serve as the reference laboratory for the analysis of samples tested with AclarusDx, its blood-based test intended to help in the diagnosis of Alzheimer’s disease (AD) and which is currently being introduced in the French IVD market. This agreement follows the successful technology transfer that was performed between Exonhit and Almac during the last few months.

Rosetta Genomics and UC Davis Researchers to Develop and Validate microRNA Biomarker to Predict Response to Neoadjuvant Chemotherapy in Bladder Cancer

Rosetta Genomics, a leading developer and provider of microRNA-based molecular diagnostic tests, announces it has entered into a collaboration with the University of California, Davis (“UC Davis” or the “University”) to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that is predictive of patient response to neoadjuvant chemotherapy. The collaboration allows for UC Davis researchers to continue using Rosetta’s platforms and microRNAs to further discover new biomarkers and validate their results.

BGI Expanding Proteomics Services to Include Mass Spectrometry

Earlier this month, Adam Bonislawski at GenomeWeb’s Proteomonitor reported that China-based BGI intends to expand its proteomics offerings and buy ~50 new mass spectrometers over the next two years. This diversification into clinical and drug-development services is a forward-thinking move for the genomics/bioinformatics giant and one that should be taken seriously by current proteomics service providers.

NextGen Sciences Launches Multiple Protein Cerebrospinal Fluid (CSF) CNS Disease Biomarker Assay

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification. The assay simultaneously measures 43 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer’s, Parkinson’s, multiple sclerosis and ALS diseases. The launch of csfdiscovery43 is the next step in NextGen Sciences strategy of becoming a leading player in the growing CNS and oncology biomarker markets.